Navigation Links
Anesiva Announces New Zingo Marketing and Distribution Agreement
Date:4/29/2008

most common adverse events with Zingo were redness (erythema), red dots (petechiae) and swelling (edema). In March 2008, Anesiva submitted a supplemental new drug application (sNDA) to expand the label indication for Zingo to include adults, based on a positive Phase 3 trial in nearly 700 patients.

About Anesiva and its Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. The second product in Anesiva's pipeline, Adlea(TM), has been shown to reduce pain after only a single administration for weeks to months in multiple settings mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA, USA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
2. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
3. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
4. Anesiva Appoints Daniel Janney to Board of Directors
5. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
6. Anesiva Announces Completion of Common Stock Offering
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
9. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
10. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , Mar. 05, 2015 Research and Markets ... the "Mature Biotech Outlook 2015: New Therapy Ventures ... offering. All biotech companies - Gilead ... in past year, have given a positive return and ... have been able to select therapy/niche indication where the ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 The next ... have received the CE mark (European) approval. The CE ... Free Trade Association (EFTA) and the European Union. Following ... now been granted to implants supplied by the Turkey-based ... conditions. , Osimplant's Cervical Expandable Bladed HA PEEK ...
(Date:3/4/2015)... -- In an article published and posted online today, ... review the clinical aspects of diseases caused by 5 ... article, "Clinical Management of Potential Bioterrorism-Related Conditions," was published ... New England Journal of Medicine . ... Tom Inglesby—review the clinical management of conditions resulting from ...
(Date:3/4/2015)... March 04, 2015 USDM Life ... the life sciences industry, hired David Blewitt ... Cloud Compliance Services and Solutions at USDM Life ... based applications while maintaining compliance with government regulations worldwide. ... been an accomplished life sciences regulatory and IS compliance ...
Breaking Biology Technology:Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3Latest Clinical Information On Bioterrorism Threats 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3
... announces that a new market research report is ... Top 10 Biotechnology Companies: Positioning, performance and SWOT ... Although the history of the biotechnology ... It was only much later that biological organisms ...
... GZP is pleased to announce that it has ... development support of gene therapy and somatic cell ... serious or life-threatening diseases.  New senior associates with ... expanding areas allow GZP to provide its clients ...
... ST. LOUIS, Oct. 5 ISTO Technologies, Inc. (ISTO), ... regeneration, announced today the completion of patient enrollment in ... an injectable formulation of juvenile chondrocytes designed for the ... patients enrolled at two clinical sites. All patients enrolled ...
Cached Biology Technology:Reportlinker Adds the Top 10 Biotechnology Companies: Positioning, Performance and SWOT Analyses 2Reportlinker Adds the Top 10 Biotechnology Companies: Positioning, Performance and SWOT Analyses 3Reportlinker Adds the Top 10 Biotechnology Companies: Positioning, Performance and SWOT Analyses 4Reportlinker Adds the Top 10 Biotechnology Companies: Positioning, Performance and SWOT Analyses 5Reportlinker Adds the Top 10 Biotechnology Companies: Positioning, Performance and SWOT Analyses 6Reportlinker Adds the Top 10 Biotechnology Companies: Positioning, Performance and SWOT Analyses 7Reportlinker Adds the Top 10 Biotechnology Companies: Positioning, Performance and SWOT Analyses 8Reportlinker Adds the Top 10 Biotechnology Companies: Positioning, Performance and SWOT Analyses 9Reportlinker Adds the Top 10 Biotechnology Companies: Positioning, Performance and SWOT Analyses 10Ground Zero Pharmaceuticals Announces Expansion of Global Consulting in Somatic Cell Therapies 2ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial 2ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial 3
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... the upcoming RedChip Global Online CEO Conference on January ... Gino Pereira , CEO of NXT-ID will ... lead product, the Wocket smart wallet and its full ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ( ... - A Global Market Overview" report to their offering. ... is to ensure that an individual is who she/he is ... make use of a person,s unique physical characteristics, such as ...
(Date:1/22/2015)... DETROIT , Jan. 13, 2015 Technology Showcase, Hall ... iris-based identity authentication solutions, today announced it will showcase its ... and developed by the Department of Energy,s Oak Ridge ... International Auto Show . EyeLock,s iris identity authentication technology is ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... published in the Sept. 15 edition of the Journal ... Edward H. Shortliffe, MD, PhD, points out that although ... role that information management and access play in healthcare ... informatics competency being developed in America,s future corps of ...
... RICHMOND, Va. (Sept. 14, 2010) An ... gene for schizophrenia, including a potentially causative mutation, ... The results of the research, led by ... human and molecular genetics in Virginia Commonwealth University,s ...
... clinical trial to assess the use of bone marrow-derived ... infarction (STEMI; severe heart attack) demonstrated a strong safety ... results published in the September issue of the ... adult stem cells, derived from the patient,s own bone ...
Cached Biology News:Informatics = essential MD competency 2VCU study: Team uncovers possible risk gene for schizophrenia 2First US trial of bone-marrow stem cells for heart attack patients proves safe 2
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Goat polyclonal to Als2 ( Abpromise for all tested applications). entrezGeneID: 57679 SwissProtID: Q96Q42...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Biology Products: